Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by PFG Investments LLC

PFG Investments LLC lowered its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 62.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,309 shares of the biopharmaceutical company’s stock after selling 5,621 shares during the period. PFG Investments LLC’s holdings in Intra-Cellular Therapies were worth $242,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of Intra-Cellular Therapies by 1.4% during the first quarter. Vanguard Group Inc. now owns 9,225,981 shares of the biopharmaceutical company’s stock valued at $638,438,000 after purchasing an additional 131,679 shares during the period. Avoro Capital Advisors LLC increased its stake in Intra-Cellular Therapies by 21.2% during the 2nd quarter. Avoro Capital Advisors LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock valued at $205,470,000 after buying an additional 525,000 shares during the period. Clearbridge Investments LLC raised its position in shares of Intra-Cellular Therapies by 12.3% during the 1st quarter. Clearbridge Investments LLC now owns 1,744,551 shares of the biopharmaceutical company’s stock worth $120,723,000 after buying an additional 191,416 shares in the last quarter. Perceptive Advisors LLC lifted its stake in shares of Intra-Cellular Therapies by 62.6% in the 2nd quarter. Perceptive Advisors LLC now owns 1,716,407 shares of the biopharmaceutical company’s stock worth $117,557,000 after acquiring an additional 661,052 shares during the period. Finally, Millennium Management LLC boosted its holdings in shares of Intra-Cellular Therapies by 214.5% in the second quarter. Millennium Management LLC now owns 889,102 shares of the biopharmaceutical company’s stock valued at $60,895,000 after acquiring an additional 606,358 shares in the last quarter. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Trading Up 11.4 %

Shares of ITCI opened at $85.47 on Thursday. Intra-Cellular Therapies, Inc. has a 1-year low of $46.10 and a 1-year high of $88.00. The stock has a market capitalization of $9.02 billion, a P/E ratio of -73.68 and a beta of 1.00. The business’s 50-day moving average price is $74.53 and its 200 day moving average price is $72.96.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.03. The business had revenue of $161.40 million for the quarter, compared to the consensus estimate of $157.74 million. Intra-Cellular Therapies had a negative net margin of 14.93% and a negative return on equity of 11.48%. The firm’s quarterly revenue was up 45.7% compared to the same quarter last year. During the same period last year, the firm posted ($0.45) earnings per share. On average, research analysts predict that Intra-Cellular Therapies, Inc. will post -0.6 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Mark Neumann sold 18,714 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $75.08, for a total value of $1,405,047.12. Following the completion of the sale, the executive vice president now owns 29,700 shares in the company, valued at $2,229,876. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, EVP Mark Neumann sold 18,714 shares of the company’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $75.08, for a total value of $1,405,047.12. Following the transaction, the executive vice president now owns 29,700 shares in the company, valued at $2,229,876. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Sharon Mates sold 28,680 shares of the stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $74.46, for a total transaction of $2,135,512.80. Following the completion of the sale, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at $79,696,697.34. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 175,316 shares of company stock worth $13,037,345. Corporate insiders own 3.40% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Morgan Stanley boosted their target price on Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. JPMorgan Chase & Co. boosted their price objective on Intra-Cellular Therapies from $79.00 to $81.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 21st. Cantor Fitzgerald restated an “overweight” rating and issued a $130.00 price objective on shares of Intra-Cellular Therapies in a report on Monday, September 16th. The Goldman Sachs Group lowered their target price on Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Finally, Piper Sandler raised shares of Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and upped their price target for the company from $68.00 to $92.00 in a report on Friday, September 6th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Intra-Cellular Therapies has a consensus rating of “Moderate Buy” and an average price target of $96.62.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.